Evidence map›Paper›PMID 18636631›Full record

ReviewDevelopmental disabilities research reviews2008

Velo-cardio-facial syndrome: 30 Years of study.

Robert J Shprintzen

Open access · greenAbstract readReview
In one paragraph

Review in Developmental disabilities research reviews, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 5 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 5 syntheses or guidelines pooled it, 460 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Age-Related Dysphagia Among Children with 22q11.2-Deletion Syndrome.The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Vaccine immunity in patients with 22q11.2 microdeletion syndrome.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025
    Observational
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Neural Crest.Advances in experimental medicine and biology · 2024
    Review

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Robert J ShprintzenDepartment of Otolaryngology and Communication Science, Velo-Cardio-Facial Syndrome International Center, State University of New York, Upstate Medical University, Syracuse, NY 13210, USA. shprintr@upstate.edu
SUNY Upstate Medical University · US

Funding

Biomarkers for Psychosis in Velocardiofacial SyndromeR01MH064824 · NIMH · UPSTATE MEDICAL UNIVERSITY · PI KATES, WENDY · 2002 to 2015
$7.3M
Genetic Modifiers for 22q 11.2 Deletion SyndromeR01HL084410 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI MORROW, BERNICE E · 2007 to 2010
$3.3M
Neuroanatomy and Cognition in Velocardiofacial SyndromeR01MH065481 · NIMH · UPSTATE MEDICAL UNIVERSITY · PI KATES, WENDY · 2003 to 2005
$816k
NHLBI NIH HHS 1 R01 HL 084410-01A1NHLBI NIH HHS R01 HL084410NIMH NIH HHS 1 R01 MH 065481-01A2NIMH NIH HHS 5 R01 MH 064824-03NIMH NIH HHS R01 MH064824NIMH NIH HHS R01 MH065481
6 · The paper itself

Abstract

Velo-cardio-facial syndrome is one of the names that has been attached to one of the most common multiple anomaly syndromes in humans. The labels DiGeorge sequence, 22q11 deletion syndrome, conotruncal anomalies face syndrome, CATCH 22, and Sedlacková syndrome have all been attached to the same disorder. Velo-cardio-facial syndrome has an expansive phenotype with more than 180 clinical features described that involve essentially every organ and system. The syndrome has drawn considerable attention because a number of common psychiatric illnesses are phenotypic features including attention deficit disorder, schizophrenia, and bipolar disorder. The expression is highly variable with some individuals being essentially normal at the mildest end of the spectrum, and the most severe cases having life-threatening and life-impairing problems. The syndrome is caused by a microdeletion from chromosome 22 at the q11.2 band. Although the large majority of affected individuals have identical 3 megabase deletions, less than 10% of cases have smaller deletions of 1.5 or 2.0 megabases. The 3 megabase deletion encompasses a region containing 40 genes. The syndrome has a population prevalence of approximately 1:2,000 in the United States, although incidence is higher. Although initially a clinical diagnosis, today velo-cardio-facial syndrome can be diagnosed with extremely high accuracy by fluorescence in situ hybridization and several other laboratory techniques. Clinical management is age dependent with acute medical problems such as congenital heart disease, immune disorders, feeding problems, cleft palate, and developmental disorders occupying management in infancy and preschool years. Management shifts to cognitive, behavioral, and learning disorders during school years, and then to the potential for psychiatric disorders including psychosis in late adolescence and adult years. Although the majority of people with velo-cardio-facial syndrome do not develop psychosis, the risk for severe psychiatric illness is 25 times higher for people affected with velo-cardio-facial syndrome than that of the general population. Therefore, interest in understanding the nature of psychiatric illness in the syndrome remains strong.

Indexed as

Chromosome DeletionAdolescentAdultChildChild, PreschoolChromosomes, Human, Pair 22DiGeorge SyndromeFaciesGenotypeHumansInfantIn Situ Hybridization, FluorescencePhenotypePsychotic Disorders

Identifiers

PMID18636631
PMCPMC2805186
OpenAlexW2130781239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.